Can a hormone infusion tame PCOS? early study hints at possibility
NCT ID NCT05971849
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested whether giving a continuous infusion of kisspeptin, a natural hormone, could dampen the overactive reproductive signals seen in polycystic ovary syndrome (PCOS). Eight women with PCOS received the hormone for 24 hours, and researchers measured changes in their luteinizing hormone pulses. The goal was to understand how the reproductive axis works in PCOS, not to treat symptoms directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
kisspeptin 112-121 (a natural hormone given as an IV infusion)
What this could lead to
If successful, this could help scientists understand how to calm overactive reproductive hormones in PCOS, possibly pointing toward future treatments.
What could go wrong
This is a very small, early-phase study with only 8 participants. It measures hormone changes, not health outcomes, so it may not lead to any practical treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC OVARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States